Skip to main content
Clinical Trials/NCT05213286
NCT05213286
Unknown
Not Applicable

The Development of a Screening Questionnaire to Discriminate Autism Spectrum Disorder and Schizotypal Disorder, and Validation of the Danish Version of RAADS-R

Glostrup University Hospital, Copenhagen1 site in 1 country600 target enrollmentFebruary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Glostrup University Hospital, Copenhagen
Enrollment
600
Locations
1
Primary Endpoint
ZAQ
Last Updated
4 years ago

Overview

Brief Summary

The aim of the study is to investigate the validity, reliability and clinical features of a Danish version of the Ritvo Autism Asperger Diagnostic Scale-Revised (RAADS-R). A self-reporting scale devise used as a supplementary questionnaire in diagnosing autism spectrum disorder (ASD) in adults. Furthermore the validity of novel screening questionnaire: SchiZotypal Autism Questionnaire (ZAQ), will be investigated. ZAQ is developed to discriminate Schizotypal Disorder from ASD.

Detailed Description

The study has 2 parts. Part 1: The objective is to develop and validate a self-report screening questionnaire to efficiently discriminate between Schizotypal Disorder (SD) and Autism Spectrum Disorder (ASD) within the adult population. Discriminating ASD from SD in a clinical setting is a complex and time-consuming task, as they share considerable features both at the symptomatic and the diagnostic criteria. A pilot version of this questionnaire have been developed with 139 questions and named schiZotypy Autism Questionnaire (ZAQ), to discriminate between these conditions. Part 2: RAADS-R scale, which is a clinical tool that aims to better identify autism spectrum disorders The scale is a self-administered questionnaire completed by the patient himself assisted by a clinician (psychiatrist, psychologist) which ensures the understanding of issues and the choice of answers. The scale contains 80 items including 64 questions describe specific symptoms of autism spectrum disorders and 16 questions to describe non-symptomatic behaviors. The objective of this study is to perform a complete validation of this scale in a Danish translation. For both parts of the study 600 adults will be included, 200 adults referred for assessment of autism, 200 adults with another psychiatric disorder, and 200 adults without psychiatric disease.

Registry
clinicaltrials.gov
Start Date
February 1, 2022
End Date
August 31, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Glostrup University Hospital, Copenhagen
Responsible Party
Principal Investigator
Principal Investigator

Rizwan Parvaiz

Medical doctor, Director of Autism Research

Glostrup University Hospital, Copenhagen

Eligibility Criteria

Inclusion Criteria

  • Al patient referred to the outpatient clinic for ADHD and Autism at PCG, in the research period, for diagnostic assessment of Autism Spectrum Disorder (Pervasive Developmental Disorder, infantile autism, atypical autism and Asperger Syndrome)
  • WAIS \> 85, or Raven or no-clinical suspicion and education level of 11 years or above
  • Completion of
  • Clinical assessment
  • Adult Asperger Assessment (AAA)
  • Psychopathology evaluation using DSM-V
  • A conclusion based on interdisciplinary consensus

Exclusion Criteria

  • Insufficient Danish language skills
  • Acute psychiatric illness prompting departure/dismissal from the diagnostic assessment

Outcomes

Primary Outcomes

ZAQ

Time Frame: up to 1 month

schiZotypy Autism Questionnaire

RAADS-R-DK

Time Frame: Up to 1 month

Ritvo Autism Asperger Diagnostic Scale-Revised-Danish version

Secondary Outcomes

  • AQ(Up to 1 month)
  • WHO-DAS 2.0(Up to 1 month)
  • WHO-5(Up to 1 month)

Study Sites (1)

Loading locations...

Similar Trials